Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Current Vaccination Practice in Diabetic (Diabetes I) Patients

Author(s): Yati Kumar, Sonali Sundaram* and Deepika Yadav

Volume 20, Issue 4, 2024

Published on: 06 October, 2023

Article ID: e061023221816 Pages: 9

DOI: 10.2174/0115733998260361230927002739

Price: $65

Abstract

The worldwide prevalence of diabetes, an endocrine condition, is rising quickly. The alarming rise of diabetes in recent years has emerged as a major contributor to premature death and illness among persons of working age. The potential use of immunomodulatory drugs to prevent diabetes has been a source of worry in light of recent advances in our understanding of the role of autoimmune responses in the development of diabetes. Vaccines can work in a variety of ways, including by eliminating autoreactive T-cells or by blocking the connections between immune cells. Most diabetes vaccines that have been created so far have only been evaluated in animal models, with just a small number having undergone successful human trials. In this article, the authors also look at the clinical trial research that are currently being conducted to create a prototype diabetes vaccine.

Keywords: Vaccine, diabetes, insulin, type1 diabetes, endocrine disorder, immunomodulatory drugs.

[1]
Lau D, Eurich DT, Majumdar SR, Katz A, Johnson JA. Effectiveness of influenza vaccination in working-age adults with diabetes: A pop-ulation-based cohort study. Thorax 2013; 68(7): 658-63.
[http://dx.doi.org/10.1136/thoraxjnl-2012-203109] [PMID: 23535212]
[2]
Tan EK, Lim LH, Teoh YL, Ong G, Bock HL. Influenza and seasonal influenza vaccination among diabetics in Singapore: Knowledge, attitudes and practices. Singapore Med J 2010; 51(8): 623-30.
[PMID: 20848058]
[3]
Smith SA, Poland GA. Praca Pogladowa 1998. Available from: www.dp.viamedica.pl
[4]
Alavian SM, Tabatabaei SV. The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: A meta-analysis of current literature. Vaccine 2010; 28(22): 3773-7.
[http://dx.doi.org/10.1016/j.vaccine.2010.03.038] [PMID: 20371390]
[5]
Bechini A, Ninci A, Del Riccio M, et al. A.; Impact of influenza vaccination on all-cause mortality and hospitalization for pneumonia in adults and the elderly with diabetes: A meta-analysis of observational studies. Vaccines 2020; 8(2): 263.
[http://dx.doi.org/10.3390/vaccines8020263] [PMID: 32486233]
[6]
Verstraeten T, Fletcher MA, Suaya JA, et al. Diabetes mellitus as a vaccine-effect modifier: A review. Expert Rev Vaccines 2020; 19(5): 445-53.
[http://dx.doi.org/10.1080/14760584.2020.1760098] [PMID: 32516066]
[7]
Dos Santos G, Tahrat H, Bekkat-Berkani R. Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: A systematic review. Hum Vaccin Immunother 2018; 14(8): 1853-66.
[http://dx.doi.org/10.1080/21645515.2018.1446719] [PMID: 29517396]
[8]
Wang IK, Lin CL, Chang YC, et al. Effectiveness of influenza vaccination in elderly diabetic patients: A retrospective cohort study. Vaccine 2013; 31(4): 718-24.
[http://dx.doi.org/10.1016/j.vaccine.2012.11.017] [PMID: 23153445]
[9]
Ye L, Chen J, Fang T, et al. Determinants of healthcare workers’ willingness to recommend the seasonal influenza vaccine to diabetic patients: A cross-sectional survey in Ningbo, China. Hum Vaccin Immunother 2018; 14(12): 2979-86.
[http://dx.doi.org/10.1080/21645515.2018.1496767] [PMID: 30020859]
[10]
Ye L, Fang T, Cui J, et al. The intentions to get vaccinated against influenza and actual vaccine uptake among diabetic patients in Ningbo, China: Identifying motivators and barriers. Hum Vaccin Immunother 2021; 17(1): 106-18.
[http://dx.doi.org/10.1080/21645515.2020.1761201] [PMID: 32460620]
[11]
Kesavadev J, Misra A, Das A, et al. Suggested use of vaccines in diabetes. Indian J Endocrinol Metab 2012; 16(6): 886-93.
[http://dx.doi.org/10.4103/2230-8210.102982] [PMID: 23226631]
[12]
Diepersloot RJA, Bouter KP, Beyer WEP, Hoekstra JBL, Masurel N. Humoral immune response and delayed type hypersensitivity to in-fluenza vaccine in patients with diabetes mellitus. Diabetologia 1987; 30(6): 397-401.
[http://dx.doi.org/10.1007/BF00292541] [PMID: 3678660]
[13]
Heymann AD, Shapiro Y, Chodick G, et al. Reduced hospitalizations and death associated with influenza vaccination among patients with and without diabetes. Diabetes Care 2004; 27(11): 2581-4.
[http://dx.doi.org/10.2337/diacare.27.11.2581] [PMID: 15504989]
[14]
Bloomgarden ZT. Type 2 diabetes in the young: the evolving epidemic. Diabetes Care 2004; 27: 998-1010.
[http://dx.doi.org/10.1111/j.1399-5448.2007.00338.x]
[15]
Endocrinologia C, Medica C, Sapienza L. The immune response to influenza vaccination in diabetic patients. Diabetologia 1986; 850-4.
[16]
Schillie SF, Spradling PR, Murphy TV. Immune response of hepatitis B vaccine among persons with diabetes: A systematic review of the literature. Diabetes Care 2012; 35(12): 2690-7.
[http://dx.doi.org/10.2337/dc12-0312] [PMID: 23173138]
[17]
Sheridan PA, Paich HA, Handy J, et al. The antibody response to influenza vaccination is not impaired in type 2 diabetics. Vaccine 2015; 33(29): 3306-13.
[http://dx.doi.org/10.1016/j.vaccine.2015.05.043] [PMID: 26044491]
[18]
Achtymichuk KA, Johnson JA, Al Sayah F, Eurich DT. Characteristics and health behaviors of diabetic patients receiving influenza vac-cination. Vaccine 2015; 33(30): 3549-55.
[http://dx.doi.org/10.1016/j.vaccine.2015.05.047] [PMID: 26044494]
[19]
Ocak S, Eskiocak AF. The evaluation of immune responses to hepatitis B vaccination in diabetic and non-diabetic haemodialysis patients and the use of tetanus toxoid. Nephrology 2008; 13(6): 487-91.
[http://dx.doi.org/10.1111/j.1440-1797.2008.00936.x] [PMID: 18331434]
[20]
Jiménez-Garcia R, Lopez-de-Andres A, Hernandez-Barrera V, et al. Influenza vaccination in people with type 2 diabetes, coverage, predic-tors of uptake, and perceptions. Result of the MADIABETES cohort a 7years follow up study. Vaccine 2017; 35(1): 101-8.
[http://dx.doi.org/10.1016/j.vaccine.2016.11.039] [PMID: 27890398]
[21]
Modin D, Claggett B, Køber L, et al. D.; Influenza vaccination is associated with reduced cardiovascular mortality in adults with diabetes: A nationwide cohort study. Diabetes Care 2020; 43(9): 2226-33.
[http://dx.doi.org/10.2337/dc20-0229] [PMID: 32647052]
[22]
Rodriguez-Blanco T, Vila-Corcoles A, de Diego C, et al. Relationship between annual influenza vaccination and winter mortality in diabetic people over 65 years. Hum Vaccin Immunother 2012; 8(3): 363-70.
[http://dx.doi.org/10.4161/hv.18548] [PMID: 22327503]
[23]
Goeijenbier M, van Sloten TT, Slobbe L, et al. Benefits of flu vaccination for persons with diabetes mellitus: A review. Vaccine 2017; 35(38): 5095-101.
[http://dx.doi.org/10.1016/j.vaccine.2017.07.095] [PMID: 28807608]
[24]
Satman I, Akalin S, Cakir B, Altinel S. The effect of physicians’ awareness on influenza and pneumococcal vaccination rates and corre-lates of vaccination in patients with diabetes in Turkey: An epidemiological Study “diaVAX”. Hum Vaccin Immunother 2013; 9(12): 2618-26.
[http://dx.doi.org/10.4161/hv.25826] [PMID: 23887188]
[25]
Wahid ST, Nag S, Bilous RW, Marshall SM, Robinson ACJ. Audit of influenza and pneumococcal vaccination uptake in diabetic patients attending secondary care in the northern region. Diabet Med 2001; 18(7): 599-603.
[http://dx.doi.org/10.1046/j.1464-5491.2001.00549.x] [PMID: 11553193]
[26]
Yu MC, Chou YL, Lee PL, Yang YC, Chen KT. Influenza vaccination coverage and factors affecting adherence to influenza vaccination among patients with diabetes in Taiwan. Hum Vaccin Immunother 2014; 10(4): 1028-35.
[http://dx.doi.org/10.4161/hv.27816] [PMID: 24503629]
[27]
Diepersloot RJA, Bouter KP, Hoekstra JBL. Influenza infection and diabetes mellitus. Case for annual vaccination. Diabetes Care 1990; 13(8): 876-82.
[http://dx.doi.org/10.2337/diacare.13.8.876] [PMID: 2209323]
[28]
Olatunbosun OD, Esterhuizen TM, Wiysonge CS. A cross sectional survey to evaluate knowledge, attitudes and practices regarding sea-sonal influenza and influenza vaccination among diabetics in Pretoria, South Africa. Vaccine 2017; 35(47): 6375-86.
[http://dx.doi.org/10.1016/j.vaccine.2017.10.006] [PMID: 29037580]
[29]
Rosman AS, Basu P, Galvin K, Lieber CS. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. Am J Med 1997; 103: 217–-22.
[30]
Looijmans-Van den Akker I, Verheij TJM, Buskens E, Nichol KL, Rutten GEHM, Hak E. Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients. Diabetes Care 2006; 29(8): 1771-6.
[http://dx.doi.org/10.2337/dc05-2517] [PMID: 16873778]
[31]
Beam TR Jr, Crigler ED, Goldman JK, Schiffman G. Antibody response to polyvalent pneumococcal polysaccharide vaccine in diabetics. JAMA 1980; 244(23): 2621-4.
[http://dx.doi.org/10.1001/jama.1980.03310230023016] [PMID: 7431608]
[32]
Pal R, Bhadada SK, Misra A. COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges. Diabetes Metab Syndr 2021; 15(2): 505-8.
[http://dx.doi.org/10.1016/j.dsx.2021.02.026] [PMID: 33662837]
[33]
Casanova L, Gobin N, Villani P, Verger P. Bias in the measure of the effectiveness of seasonal influenza vaccination among diabetics. Prim Care Diabetes 2016; 10(6): 398-406.
[http://dx.doi.org/10.1016/j.pcd.2016.05.005] [PMID: 27290610]
[34]
Colquhoun AJ, Nicholson KG. Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes. Epidemiol Infect 1997; 119(3): 335-41.
[35]
Aldossari KK, Alharbi MB, Alkahtani SM, Alrowaily TZ, Alshaikhi AM, Twair AA. COVID-19 vaccine hesitancy among patients with diabetes in Saudi Arabia. Diabetes Metab Syndr 2021; 15(5): 102271.
[http://dx.doi.org/10.1016/j.dsx.2021.102271] [PMID: 34500380]
[36]
DeStefano. Childhood vaccinations, vaccination timing, and risk of type 1 diabetes. Pediatrics 2001; 108(6): e112.
[http://dx.doi.org/10.1542/peds.108.6.e112]
[37]
Alvarez CE, Clichici L, Patricia Guzmán-Libreros A, Navarro-Francés M, Ena J. Survey of vaccination practices in patients with diabetes: A report examining patient and provider perceptions and barriers. J Clin Transl Endocrinol 2017; 9(15): 15-7.
[http://dx.doi.org/10.1016/j.jcte.2017.06.002] [PMID: 29067263]
[38]
Ding D, Du Y, Qiu Z, et al. Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy. J Mol Med (Berl) 2016; 94(2): 207-18.
[http://dx.doi.org/10.1007/s00109-015-1343-6] [PMID: 26407577]
[39]
Remschmidt C, Wichmann O, Harder T. Vaccines for the prevention of seasonal influenza in patients with diabetes: Systematic review and meta-analysis. BMC Med 2015; 13(1): 53.
[http://dx.doi.org/10.1186/s12916-015-0295-6] [PMID: 25857236]
[40]
Coffman RL, Sher A, Seder RA. Vaccine adjuvants: Putting innate immunity to work. Immunity 2010; 33(4): 492-503.
[http://dx.doi.org/10.1016/j.immuni.2010.10.002] [PMID: 21029960]
[41]
Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med 2013; 19(12): 1597-608.
[http://dx.doi.org/10.1038/nm.3409] [PMID: 24309663]
[42]
Lambrecht BN, Kool M, Willart MAM, Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009; 21(1): 23-9.
[http://dx.doi.org/10.1016/j.coi.2009.01.004] [PMID: 19246182]
[43]
Oleszycka E, Lavelle EC. Immunomodulatory properties of the vaccine adjuvant alum. Curr Opin Immunol 2014; 28: 1-5.
[http://dx.doi.org/10.1016/j.coi.2013.12.007] [PMID: 24463269]
[44]
Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356(15): 1517-26.
[http://dx.doi.org/10.1056/NEJMoa065213] [PMID: 17429083]
[45]
Ren K, Torres R. Role of interleukin-1β during pain and inflammation. Brain Res Brain Res Rev 2009; 60(1): 57-64.
[http://dx.doi.org/10.1016/j.brainresrev.2008.12.020] [PMID: 19166877]
[46]
Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev 2011; 22(4): 189-95.
[http://dx.doi.org/10.1016/j.cytogfr.2011.10.001] [PMID: 22019906]
[47]
Banerjee M, Saxena M. Interleukin-1 (IL-1) family of cytokines: Role in type 2 diabetes. Clin Chim Acta 2012; 413(15-16): 1163-70.
[http://dx.doi.org/10.1016/j.cca.2012.03.021] [PMID: 22521751]
[48]
Handa M, Vanegas S, Maddux BA, et al. XOMA 052, an anti-IL-1β monoclonal antibody, prevents IL-1β-mediated insulin resistance in 3T3-L1 adipocytes. Obesity 2013; 21(2): 306-9.
[http://dx.doi.org/10.1002/oby.20004] [PMID: 23401297]
[49]
Zha J, Chi X, Yu X, et al. Interleukin-1β-targeted vaccine improves glucose control and β-cell function in a diabetic KK-Ay mouse model. PLoS One 2016; 11(5): e0154298.
[http://dx.doi.org/10.1371/journal.pone.0154298] [PMID: 27152706]
[50]
Spohn G, Schori C, Keller I, et al. Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes. Mol Ther Methods Clin Dev 2014; 1: 14048.
[http://dx.doi.org/10.1038/mtm.2014.48] [PMID: 26015986]
[51]
Pagni PP, Bresson D, Rodriguez-Calvo T, et al. Combination therapy with an anti-IL-1β antibody and GAD65 DNA vaccine can reverse recent-onset diabetes in the RIP-GP mouse model. Diabetes 2014; 63(6): 2015-25.
[http://dx.doi.org/10.2337/db13-1257] [PMID: 24520125]
[52]
Cavelti-Weder C, Timper K, Seelig E, et al. Development of an interleukin-1β vaccine in patients with type 2 diabetes. Mol Ther 2016; 24(5): 1003-12.
[http://dx.doi.org/10.1038/mt.2015.227] [PMID: 26686385]

Rights & Permissions Print Cite
Article Metrics
9
3
© 2024 Bentham Science Publishers | Privacy Policy